Urogen Pharma Soars 3.26% Post FDA Approval & Nasdaq Listing!
Monday, Jun 9, 2025 4:34 am ET1min read
URGN--
Urogen Pharma Ltd. surged 3.26% in premarket trading, driven by the FDA's accelerated approval of its first commercial product, Jelmyto, for low-grade upper tract urothelial cancer in 2020, and the company's announcement of granting restricted stock units to 27 new employees under Nasdaq listing rules, indicating its commitment to expanding the team to support product commercialization and pipeline development.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet